Coronavirus (COVID-19) Statement

We continue to closely monitor the situation surrounding the COVID-19 pandemic and are following the published recommendations of the CDC and the American Academy of Ophthalmology. We will continue to see our patients and treat any urgent/emergent needs.

With all of our offices open, the following protocols are in place:

1) We have greatly expanded measures to disinfect our office including cleaning between each patient appointment.

2) To limit any potential exposure, we ask you NOT to bring any non-essential person(s) with you to the appointment.

3) If someone must accompany you to your appointment, we ask that they do not enter the office, if at all possible.

4) If you have an upcoming appointment and identify with the following statements, please do not come directly to the office, but instead call us:

• Fever greater than 100.4

• Respiratory symptoms or difficulty breathing

• Exposed to someone with COVID-19 in the past 14 days

• Placed in self/hospital quarantine by medical doctor

 Your health and that of our staff is our guiding priority and we continue to update our protocol to ensure safety for everyone. If you have questions regarding these evolving protocols, please contact our office.

         Dr. Christensen CURRICULUM VITAE

Ryan D. Christensen, M.D.
 

WORK HISTORY

2010 - PRESENT:

  • Retina Associates, LLC
    Santa Fe Medical Building
    9301 West 74th Street
    Suite 210
    Shawnee Mission, KS 66204
  • Retina Associates, LLC
    6201 College Boulevard
    Suite 200
    Overland Park, KS 66211
  • Retina Associates. LLC
    4100 North Mulberry Drive
    Suite 100
    Kansas City, MO 64116
  • Retina Associates, LLC
    6001 SW 6th Avenue
    Suite 300
    Topeka, KS 66615
  • Retina Associates, LLC
    3700 West 10th Street
    Suite 101
    Sedalia, MO 65301
  • Retina Associates, LLC
    100 NE Missouri Road
    Suite 203
    Lee's Summit, MO 64086

2008 - 2009

  • University of Kansas School of Medicine - Kansas City Clinical Faculty, Vitreoretinal Medicine and Surgery

1990 - 2004

  • USD 385 - Andover Kansas Substitute Teacher, 2004
  • USD 266 - Maize, Kansas Substitute Teacher, 2004
  • Boy Scouts of America, Philmont Scout Ranch, Camp Medic, 2003
  • Kansas State University, Department of Anatomy and Physiology, Student Teaching Assistant - Cadaver Lab, 2000
  • Kansas State University, Department of Anatomy and Physiology, Student Teaching Assistant - Human Anatomy, 1999
  • Fry Eye Associates, Garden City Kansas, Ophthalmic Technician, 1998 - 1999
  • Christensen Animal Clinic, Garden City, Kansas, Veterinary Assistant, 1990 - 1995

EDUCATION:

  • Retina Associates, P.A. – Shawnee Mission, KS 2008-2010
    -Vitreoretinal Fellowship
  • University of Kansas School of Medicine – Kansas City, KS 2005-2008
    -Ophthalmology Residency
  • University of Kansas School of Medicine – Wichita, KS 2004 -2005
    -Internal Medicine Internship
  • University of Kansas School of Medicine – Wichita, KS 2002-2004
    -Clinical clerkship – Medical School
  • University of Kansas School of Medicine – Kansas City, KS 2000-2002
    -Basic Science Clerkship – Medical School
  • Kansas State University – Manhattan, KS 1995-2000
    -Bachelor of Science – Biology
  • Garden City Community College – Garden City, KS 1996-1997
  • Garden City High School – Garden City, KS 1991-1995

PROFESSIONAL ASSOCIATIONS:

  • American Academy of Ophthalmology
  • American Board of Ophthalmology
  • Kansas City Society of Ophthalmology and Otolaryngology
  • Kansas City Society of Ophthalmology and Otolaryngology Journal Club
  • Kansas Medical Society
  • Kansas Society of Eye Physicians and Surgeons
  • Missouri Society of Eye Physicians and Surgeons
  • Missouri State Medical Association

RESEARCH:

  • Alcon:  RTH258-C001, Sub-Investigator, RTH258 versus Aflibercept for Patients With NVAMD, 05/2015 - 05/2018.
  • Allergan: 208397-001, Sub-Investigator, AGN-208397 for the Treatment of Macular Edema Secondary to Retinal Vein Occlusion, 11/2010 - 2013.
  • Eyetech: EOP1024, Sub-Investigator, Evaluating the Effects of Intravitreal Injections of Pegaptanib for NVAMD on the Corneal Endothelium, 2010 - 04/2012.
  • Genentech: FVF4168g, Sub-Investigator, Intravitreal Injection of Ranibizumab for Diabetic Macular Edema, 2008 - 12/2012
  • Genentech: FVF4166g, Sub-Investigator, Intravitreal Injection of Ranibizumab for Central Retinal Vein Occlusion, 2008-2010.
  • Genentech: FVF4165g, Sub-Investigator, Intravitreal Injection of Ranibizumab for Branch Retinal Vein Occlusion 2008-2010.
  • Genentech: FVF3426g, Sub-Investigator, Intravitreal Injection of Ranibizumab for BRVO & CRVO Patients who Completed 
    Genentech Sponsored Ranibizumab Study 2009-2010.
  • Genentech: FVF4579g, Sub-Investigator, Intravitreal Injection of Ranibizumab for Subfoveal Neovascular AMD 2009 - 09/2012.
  • Genentech: FVF4967g, Sub-Investigator, Intravitreal Injection of Ranibizumab for BRVO, CRVO, & HRVO , 03/2011 - 01/2013.
  • Genentech: GX29176, Sub-Investigator, Inravitreal Injection or Lampalizumab for GA Secondary to NNVAMD, 11/2014 - 04/2018.
  • Genentech: GX30191, Sub-Investigator, Intravitreal Lampalizumab for Patients With GA Who Completed the Parent Study GX29176, 11/2016 - 04/2018.
  • Genentech: GR40548, Sub-Investigator, Port Delivery System versus Intravitreal Ranibizumab for Patients with NVAMD, 11/2018 - present.
  • Genentech: GR40349, Sub-Investigator, Intravitreal Faricimab for Patients With DME, 11/2018 - present.
  • Lux BioScience: LX211-11, Sub-Investigator, Study to Assess the Efficacy and Safety of Voclosporin as Therapy in Subjects With Active, Noninfectious, Intermediate, Posterior or Pan-Uveitis, 01/2011 - 01/2012.
  • MyLan: MYL-1701P-3001, Sub-Investigator, MYL-1701P versus Aflibercept for Patients With DME, 08/2018 - present.
  • Novartis: CRTH258B2301, Sub-Investigator, Brolucizumab versus Aflibercept for Patients With Visual Impairment Due to DME, 09/2018 - present.
  • Novartis: CRTH258AUS04, Sub-Investigator, Brolucizumab versus Aflibercept for Patients With NVAMD With Persistent Sub-Retinal Fluid, 12/2018 - present.
  • Ophthotech: OPH3000, Sub-Investigator, Intravitreal Injection of Volocixumab in Combination with Ranibizumab for NVAMD, 2008 - 2009.
  • Ophthotech: OPH1001, Sub-Investigator, Intravitreal Injection of E10030 in Combination with Ranibizumab for NVAMD 2010 - 11/2011.
  • Ophthotech: OPH1003, Sub-Investigator, Intravitreal Injection of Fovista in Combination With Ranibizumab versus Ranibizumab Monotherapy for Patients With NVAMD, 10/2013 - 02/2017.
  • Opthea:  OPT-302-1002, Sub-Investigator, Intravitreal OPT-302 in Combination With Ranibizumab versus Ranibizumab Alone for NVAMD, 12/2017 - present.
  • PanOptica:  PAN01-010, Sub-Investigator, Topical Ocular PAN-90806 for Patients With NVAMD, 02/2014 - 02/2016.
  • NEI: SCORE2, Sub-Investigator, Bevacizumab versus Aflibercept for Macular Edema Secondary to Central Retinal Vein Occlusion, 10/2014 - 10-2016.
  • Regeneron: R2176-3-AMD-1417, Sub-Investigator, REGN2176-3 for Patients With NVAMD, 05/2015 - 04/2017.
  • Regeneron: R910-3-DME-1518, Sub-Investigator, REGN910-3 for Patients With DME, 04/2016 - 10/2017.

SCHOLARLY PRESENTATIONS

  • Fluorescein Angiography #101, 2008/09 - KU Eye - Monthly lecture series
  • Posterior Parasitic Uveitis, 11/2007 - KU Eye Grand Rounds
  • Parasitic Uveitis: Worm in the Eye!! 02/2007 - High Plain’s Eye Society Winter Symposium
  • Adherence to Preferred Practice Patterns in ARMD, 06/2007 - KU Eye Grand Rounds
  • AAO Mid-Year Forum 2007, 06/2007 - KU Eye Grand Rounds
  • Orbital Masses – A Differential Diagnosis, 05/2007 - Children’s Mercy Hospital Grand Rounds
  • Eyelid Tumors - Clinical Diagnosis and Histology 101, 09/2006 - KU Eye Grand Rounds
  • Herpetic Corneal Disorders, 07/2006 - KU Eye New Resident Orientation
  • Common Corneal Disorders, 07/2006 - KU Eye New Resident Orientation
  • Cogan's Syndrome - Oculovestibuloauditory Syndrome, 06/2006 -KU Eye Resident Research Day
  • LASIK and Excimer Laser Evolution, 03/2006 - KU Eye Grand Rounds
  • Aceruloplasminemia – Fundus and Fluorescein Angiography, 04/2006 - KU Medical Center Internal Medicine Grand Rounds
  • The Red Eye - A Differential Diagnosis, 07/2005 - KU Medical Center Pediatrics Morning Report

A Vision to be the Best

As the largest group of Retina specialists in the Greater Kansas City, Topeka, Sedalia and surrounding areas we offer multiple professional offices to serve you.  Each of our offices are staffed and equipped to provide the highest level of health care service and access in a comfortable environment.

Dr. Christensen is currently seeing patients at our Overland Park, Kansas City, Topeka and Lee's Summit locations. 

Retina Associates, PA logo

Retina Associates, LLC

Retina Associates, LLC is an advanced medical practice devoted to the diagnosis and treatment of retinal, macular, and vitreous diseases. Together, our eye care physicians belong to various prestigious organizations: 

  • American Board of Ophthalmology
  • American Academy of Ophthalmology
  • Association for Research in Vision and Ophthalmology
  • American College of Surgeons
  • American Society of Retina Specialists

Our mission is to help every patient preserve or restore their sight through our advanced treatment options. To discuss your needs with one of our doctors, request an appointment online or call us at (913) 831-7400.

Contact Us

Rate, Review & Explore

Social Accounts Sprite
Google map image of our location in Shawnee Mission, KS

Shawnee Mission Office

9301 W 74th St
Ste 210
Shawnee Mission, KS 66204

Open Today 8:00am - 5:00pm

What is the best time for you?

Add additional time

Tell us a bit about yourself...

(913) 831-7400 Send a message